JP2019519519A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019519519A5 JP2019519519A5 JP2018560887A JP2018560887A JP2019519519A5 JP 2019519519 A5 JP2019519519 A5 JP 2019519519A5 JP 2018560887 A JP2018560887 A JP 2018560887A JP 2018560887 A JP2018560887 A JP 2018560887A JP 2019519519 A5 JP2019519519 A5 JP 2019519519A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- mutation
- mammal
- subject
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000035772 mutation Effects 0.000 claims description 13
- 241000124008 Mammalia Species 0.000 claims description 10
- 201000001441 melanoma Diseases 0.000 claims description 9
- 244000144972 livestock Species 0.000 claims description 7
- KSERXGMCDHOLSS-LJQANCHMSA-N n-[(1s)-1-(3-chlorophenyl)-2-hydroxyethyl]-4-[5-chloro-2-(propan-2-ylamino)pyridin-4-yl]-1h-pyrrole-2-carboxamide Chemical compound C1=NC(NC(C)C)=CC(C=2C=C(NC=2)C(=O)N[C@H](CO)C=2C=C(Cl)C=CC=2)=C1Cl KSERXGMCDHOLSS-LJQANCHMSA-N 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 5
- 230000001394 metastastic effect Effects 0.000 claims description 5
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 5
- 241000282412 Homo Species 0.000 claims description 4
- 102000043136 MAP kinase family Human genes 0.000 claims description 4
- 108091054455 MAP kinase family Proteins 0.000 claims description 4
- 241000288906 Primates Species 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 3
- 239000003981 vehicle Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021214205A JP2022034068A (ja) | 2013-12-20 | 2021-12-28 | 非ｅｒｋ ｍａｐｋ経路阻害剤耐性のがんを処置するための方法および組成物 |
| JP2024108968A JP2024133638A (ja) | 2013-12-20 | 2024-07-05 | 非ｅｒｋ ｍａｐｋ経路阻害剤耐性のがんを処置するための方法および組成物 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361919551P | 2013-12-20 | 2013-12-20 | |
| US15/161,137 | 2016-05-20 | ||
| US15/161,137 US20160317519A1 (en) | 2013-12-20 | 2016-05-20 | Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers |
| PCT/US2017/033843 WO2017201532A1 (en) | 2013-12-20 | 2017-05-22 | Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021214205A Division JP2022034068A (ja) | 2013-12-20 | 2021-12-28 | 非ｅｒｋ ｍａｐｋ経路阻害剤耐性のがんを処置するための方法および組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019519519A JP2019519519A (ja) | 2019-07-11 |
| JP2019519519A5 true JP2019519519A5 (enExample) | 2020-06-25 |
| JP7427212B2 JP7427212B2 (ja) | 2024-02-05 |
Family
ID=53403903
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018560887A Active JP7427212B2 (ja) | 2013-12-20 | 2017-05-22 | 非ｅｒｋ ｍａｐｋ経路阻害剤耐性のがんを処置するための方法および組成物 |
| JP2021214205A Withdrawn JP2022034068A (ja) | 2013-12-20 | 2021-12-28 | 非ｅｒｋ ｍａｐｋ経路阻害剤耐性のがんを処置するための方法および組成物 |
| JP2024108968A Pending JP2024133638A (ja) | 2013-12-20 | 2024-07-05 | 非ｅｒｋ ｍａｐｋ経路阻害剤耐性のがんを処置するための方法および組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021214205A Withdrawn JP2022034068A (ja) | 2013-12-20 | 2021-12-28 | 非ｅｒｋ ｍａｐｋ経路阻害剤耐性のがんを処置するための方法および組成物 |
| JP2024108968A Pending JP2024133638A (ja) | 2013-12-20 | 2024-07-05 | 非ｅｒｋ ｍａｐｋ経路阻害剤耐性のがんを処置するための方法および組成物 |
Country Status (15)
| Country | Link |
|---|---|
| US (5) | US20160317519A1 (enExample) |
| EP (2) | EP4653055A2 (enExample) |
| JP (3) | JP7427212B2 (enExample) |
| KR (2) | KR20230025941A (enExample) |
| CN (2) | CN109475541A (enExample) |
| AU (3) | AU2017267804B2 (enExample) |
| BR (1) | BR112018073786A2 (enExample) |
| CA (1) | CA3024703A1 (enExample) |
| CL (1) | CL2018003282A1 (enExample) |
| IL (2) | IL294056A (enExample) |
| MX (2) | MX392121B (enExample) |
| RU (1) | RU2018145048A (enExample) |
| SG (1) | SG11201810287RA (enExample) |
| WO (2) | WO2015095842A2 (enExample) |
| ZA (2) | ZA201808480B (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| MX358640B (es) | 2008-01-04 | 2018-08-29 | Intellikine Llc | Isoquinolin-1 (2h) -onas y tieno [2,3-d]pirimidin-4(3h) -onas substituidas, y metodos de uso de las mismas. |
| TWI546305B (zh) | 2011-01-10 | 2016-08-21 | 英菲尼提製藥股份有限公司 | 製備異喹啉酮之方法及異喹啉酮之固體形式 |
| US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
| CN105102000B (zh) | 2012-11-01 | 2021-10-22 | 无限药品公司 | 使用pi3激酶亚型调节剂的癌症疗法 |
| WO2015095842A2 (en) * | 2013-12-20 | 2015-06-25 | Biomed Valley Discoveries, Inc. | Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers |
| WO2015160975A2 (en) | 2014-04-16 | 2015-10-22 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| WO2017106492A1 (en) * | 2015-12-18 | 2017-06-22 | Ignyta, Inc. | Combinations for the treatment of cancer |
| WO2017180817A1 (en) * | 2016-04-15 | 2017-10-19 | Musc Foundation For Research Development | Treatment of septicemia and ards with erk inhibitors |
| MX2018012471A (es) * | 2016-04-15 | 2019-02-21 | Genentech Inc | Metodos de diagnostico y terapeuticos para el cancer. |
| EP3474856B1 (en) | 2016-06-24 | 2022-09-14 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| WO2018134254A1 (en) | 2017-01-17 | 2018-07-26 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| MX2019013634A (es) * | 2017-05-16 | 2020-01-21 | Biomed Valley Discoveries Inc | Composiciones y metodos para tratar cancer con mutaciones de braf atipicas. |
| EP3700530B1 (en) * | 2017-10-26 | 2023-04-19 | Xynomic Pharmaceuticals, Inc. | Crystalline salts of a b-raf kinase inhibitor |
| AU2019253706A1 (en) * | 2018-04-09 | 2020-11-26 | G1 Therapeutics, Inc. | Treatment of cancers having driving oncogenic mutations |
| CN110656172A (zh) * | 2019-01-14 | 2020-01-07 | 南方医科大学珠江医院 | 一种预测小细胞肺癌对ep化疗方案敏感性的分子标志物及试剂盒 |
| US12122787B2 (en) | 2019-09-20 | 2024-10-22 | Shanghai Jemincare Pharmaceuticals Co., Ltd | Fused pyridone compound, and preparation method therefor and use thereof |
| EP4073102A4 (en) | 2019-12-12 | 2024-05-08 | Ting Therapeutics LLC | Compositions and methods for the prevention and treatment of hearing loss |
| KR102697384B1 (ko) * | 2022-01-13 | 2024-08-22 | 팔라디바이오텍 주식회사 | 리셉터 티로신 키나제 저해제를 탐색하는 방법 |
| CN115177622B (zh) * | 2022-07-19 | 2024-09-17 | 中南大学湘雅二医院 | 多个化合物在制备治疗骨髓增殖性肿瘤的药物中的应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69430909T2 (de) | 1993-03-19 | 2003-02-27 | Sequenom, Inc. | Dns-sequenzbestimmung durch massenspektrometrie auf dem weg des abbaus mit exonuklease |
| US6140053A (en) | 1996-11-06 | 2000-10-31 | Sequenom, Inc. | DNA sequencing by mass spectrometry via exonuclease degradation |
| US7601497B2 (en) | 2000-06-15 | 2009-10-13 | Qiagen Gaithersburg, Inc. | Detection of nucleic acids by target-specific hybrid capture method |
| US7439016B1 (en) | 2000-06-15 | 2008-10-21 | Digene Corporation | Detection of nucleic acids by type-specific hybrid capture method |
| GB0320059D0 (en) | 2003-08-27 | 2003-10-01 | Solexa Ltd | A method of sequencing |
| PL3305776T3 (pl) | 2004-05-14 | 2020-03-31 | Vertex Pharmaceuticals Incorporated | Związki pirolowe jako inhibitory kinaz białkowych erk i kompozycje farmaceutyczne zawierające te związki |
| US7582623B2 (en) | 2004-05-20 | 2009-09-01 | The Regents Of The University Of California | Photoactive metal nitrosyls for blood pressure regulation and cancer therapy |
| US20060228721A1 (en) | 2005-04-12 | 2006-10-12 | Leamon John H | Methods for determining sequence variants using ultra-deep sequencing |
| JP2008545670A (ja) * | 2005-05-27 | 2008-12-18 | バイエル・ヘルスケア・アクチェンゲゼルシャフト | 疾患を処置するためのジアリールウレア類を含む組合せ治療 |
| TWI394839B (zh) | 2008-10-27 | 2013-05-01 | Qiagen Gaithersburg Inc | 快速結果雜交捕捉法及系統 |
| KR20120046018A (ko) | 2010-10-04 | 2012-05-09 | 삼성테크윈 주식회사 | 단일 뉴클레오티드 다형성의 실시간 ｐｃｒ 검출 |
| WO2012125848A2 (en) | 2011-03-16 | 2012-09-20 | Baylor College Of Medicine | A method for comprehensive sequence analysis using deep sequencing technology |
| KR20240146112A (ko) * | 2012-08-17 | 2024-10-07 | 에프. 호프만-라 로슈 아게 | 코비메티닙 및 베무라피닙을 투여함을 포함하는 흑색종의 조합 치료법 |
| EP2953622B1 (en) * | 2013-02-11 | 2021-03-24 | Abraxis BioScience, LLC | Methods of treating melanoma |
| CN104994879A (zh) * | 2013-02-22 | 2015-10-21 | 霍夫曼-拉罗奇有限公司 | 治疗癌症和预防药物抗性的方法 |
| WO2015095833A1 (en) * | 2013-12-20 | 2015-06-25 | Biomed Valley Discoveries, Inc. | Treatment of hematologic cancers |
| WO2015095834A2 (en) * | 2013-12-20 | 2015-06-25 | Biomed Valley Discoveries, Inc. | Cancer treatments using erk1/2 and bcl-2 family inhibitors |
| WO2015095842A2 (en) * | 2013-12-20 | 2015-06-25 | Biomed Valley Discoveries, Inc. | Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers |
| RU2722784C2 (ru) | 2013-12-20 | 2020-06-03 | Байомед Вэлли Дискавериз, Инк. | Лечение злокачественных опухолей с применением комбинаций ингибиторов erk и raf |
| WO2016025649A1 (en) * | 2014-08-13 | 2016-02-18 | Celgene Avilomics Research, Inc. | Combinations of an erk inhibitor and a dot1l inhibitor and related methods |
| US9676746B2 (en) * | 2015-01-30 | 2017-06-13 | Biomed Valley Discoveries, Inc. | Crystalline forms of C21H22Cl2N4O2 |
| ES2830044T3 (es) * | 2015-01-30 | 2021-06-02 | Biomed Valley Discoveries Inc | Malonato de C21H22C12N4O2 cristalino |
-
2014
- 2014-12-19 WO PCT/US2014/071749 patent/WO2015095842A2/en not_active Ceased
-
2016
- 2016-05-20 US US15/161,137 patent/US20160317519A1/en not_active Abandoned
-
2017
- 2017-05-22 MX MX2018014231A patent/MX392121B/es unknown
- 2017-05-22 CA CA3024703A patent/CA3024703A1/en active Pending
- 2017-05-22 SG SG11201810287RA patent/SG11201810287RA/en unknown
- 2017-05-22 KR KR1020237004648A patent/KR20230025941A/ko not_active Ceased
- 2017-05-22 WO PCT/US2017/033843 patent/WO2017201532A1/en not_active Ceased
- 2017-05-22 EP EP25207698.9A patent/EP4653055A2/en active Pending
- 2017-05-22 BR BR112018073786-0A patent/BR112018073786A2/pt not_active Application Discontinuation
- 2017-05-22 CN CN201780044255.XA patent/CN109475541A/zh active Pending
- 2017-05-22 CN CN202510671199.9A patent/CN120501744A/zh active Pending
- 2017-05-22 IL IL294056A patent/IL294056A/en unknown
- 2017-05-22 KR KR1020187037187A patent/KR20190009804A/ko not_active Ceased
- 2017-05-22 US US16/302,955 patent/US11246859B2/en active Active
- 2017-05-22 IL IL263108A patent/IL263108B/en unknown
- 2017-05-22 AU AU2017267804A patent/AU2017267804B2/en active Active
- 2017-05-22 EP EP17800334.9A patent/EP3458056B1/en active Active
- 2017-05-22 JP JP2018560887A patent/JP7427212B2/ja active Active
- 2017-05-22 RU RU2018145048A patent/RU2018145048A/ru not_active Application Discontinuation
- 2017-10-30 US US15/797,593 patent/US10881646B2/en active Active
-
2018
- 2018-11-19 CL CL2018003282A patent/CL2018003282A1/es unknown
- 2018-11-20 MX MX2022005473A patent/MX2022005473A/es unknown
- 2018-12-14 ZA ZA2018/08480A patent/ZA201808480B/en unknown
-
2020
- 2020-10-23 US US17/078,255 patent/US20210038587A1/en active Pending
- 2020-12-11 ZA ZA2020/07734A patent/ZA202007734B/en unknown
-
2021
- 2021-12-23 US US17/561,076 patent/US20220117950A1/en active Pending
- 2021-12-28 JP JP2021214205A patent/JP2022034068A/ja not_active Withdrawn
-
2023
- 2023-07-11 AU AU2023204587A patent/AU2023204587B2/en active Active
-
2024
- 2024-07-05 JP JP2024108968A patent/JP2024133638A/ja active Pending
-
2025
- 2025-06-19 AU AU2025204585A patent/AU2025204585A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019519519A5 (enExample) | ||
| RU2018145048A (ru) | Способы и композиции для лечения злокачественных опухолей, резистентных к ингибиторам пути non-erk марк | |
| JP2018111728A5 (enExample) | ||
| JP2017105763A5 (enExample) | ||
| JP2014526503A5 (enExample) | ||
| US9161946B2 (en) | Dosing methods for treating disease | |
| CN111065639A (zh) | 一类细胞周期依赖性激酶的降解剂、其制备方法、药物组合物及其用途 | |
| FI3157527T3 (fi) | Ezh2-inhibiittoreita lymfoman hoitoon | |
| JP2017529382A5 (enExample) | ||
| JP2015515985A5 (enExample) | ||
| BR112012019374A2 (pt) | composição farmacêutica, pellet de liberação prolongada, composição farmacêutica oral, método para tratamento de uma doença neurodegenerativa ou um dano ao sistema nervoso em um indivíduo necessitado do mesmo e método para preparação de uma formulação de liberação prolongada de um agente ativo | |
| JP2016515561A5 (enExample) | ||
| EA201591290A2 (ru) | Креноланиб для лечения пролиферативных расстройств, связанных с мутацией flt3 | |
| FI3307271T3 (fi) | Pyruvaattikinaasin aktivaattorien käyttämisen menetelmä | |
| JP2017533201A5 (enExample) | ||
| MX383665B (es) | Composiciones de donepezilo y métodos para tratar la enfermedad de alzheimer. | |
| JP2016516074A5 (enExample) | ||
| RU2020109376A (ru) | Применение антагонистов рецептора ep4 для лечения nash- ассоциированного рака печени | |
| JP2016525097A5 (enExample) | ||
| EA201492010A1 (ru) | Применение высокой дозы лахинимода для лечения рассеянного склероза | |
| JP2019522032A5 (enExample) | ||
| JP2018509388A5 (enExample) | ||
| JP2019516739A5 (enExample) | ||
| JP2018537507A5 (enExample) | ||
| JP2018537513A5 (enExample) |